Loading news...
Arturo Molina sold 9,514 directly on Jan. 20, 2026, generating a transaction value of approximately $784,700 at a reported price of $82.48 per share. This sale represented 8.91% of Dr. Molina's direct holdings, reducing his stake from 106,780 to 97,266 shares.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 4,068 shares of the business's stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total value of $338,416.92. Following the completion of the transaction, the chief executive officer directly owned 574,505
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $82.00, for a total value of $410,000.00. Following the sale, the insider directly owned 84,115 shares in the company, valued
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) insider Arturo Md Molina sold 13,151 shares of the firm's stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the transaction, the insider directly owned 84,115 shares in
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CFO Asif Ali sold 46,203 shares of the stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the sale, the chief financial officer directly owned 60,320 shares of the
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 19,315 shares of the company's stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $84.59, for a total transaction of $1,633,855.85. Following the completion of the sale, the chief executive officer owned 574,505 shares
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 24,890 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $84.03, for a total value of $2,091,506.70. Following the completion of the sale, the chief executive officer owned 574,505 shares in
Protagonist Therapeutics, Inc. (PTGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating
Assenagon Asset Management S.A. lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 28.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,756 shares of the company's stock after selling 26,119 shares during
Bosun Asset Management LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,226 shares of the company's stock, valued at approximately $565,000. Other hedge funds and
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide's efficacy and safety and demonstrate du.
Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 11.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,913 shares of the company's stock after acquiring an
Aviva PLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 28.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,435 shares of the company's stock after selling 3,765 shares during the quarter. Aviva PLC's holdings in Protagonist
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.54 per share a year ago.
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67th Annual American Society of Hematology (ASH) meeting in December First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist IND-enabling studies progressing as planned with triple-GLP/GIP/GCG agonists PN-477sc and PN-477o Oral hepcidin development candidate expected to be nominated by year end Cash, cash equivalents and marketable securities of $678.8 million as of September 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / November 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. "2025 continues to be a highly productive year with significant accomplishments in both partnered and wholly owned programs," said Dinesh V.
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida, from December 6-9, 2025. ASH Presentation Details: Presenting Author: Andrew Kuykendall, MD (Moffitt Cancer Center) Publication Number: 81 Title: Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study Oral Session Name: 634.
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.